Navigation Links
ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
Date:7/23/2013

equency of adverse events was lower in the ARRY-502 group including fewer asthma exacerbations versus the placebo group.  There were no treatment-emergent serious adverse events in patients receiving ARRY-502; all treatment-related adverse events were either mild or moderate in severity.  A total of 15 (11 in the placebo group, 4 in the ARRY-502 group) out of 184 patients discontinued the study early, primarily due to exacerbations of asthma (5 in the placebo group, 1 in the ARRY-502 group).

"There remains a significant need for more convenient, safe and effective therapies for patients with persistent allergic asthma," said Sally Wenzel M.D., Professor of Medicine and Director of the Asthma Institute at the University of Pittsburgh and lead investigator of this trial.
"ARRY-502 is the first oral non-steroidal drug since Singulair® (montelukast) to demonstrate clinically meaningful activity in allergic asthma and represents a potential new oral therapy that may meet these needs."

Ron Squarer, Chief Executive Officer of Array, noted, "With many asthma patients poorly controlled on currently available therapies, a drug targeting a novel, non-overlapping mechanism may present an important new option for millions of patients.  We are seeking an appropriate partner to develop ARRY-502 to its full potential." 

Conference Call InformationArray will hold a conference call on Tuesday, July 23, 2013, at 9:00 a.m. eastern time to discuss these results.  Ron Squarer, Chief Executive Officer, will lead the call.Conference Call InformationDate:Tuesday, July 23, 2013Time:9:00 a.m. eastern timeToll-Free:(888) 771-4371Toll:(847) 585-4405Pass Code:35320183Webcast, including Replay and Conference Call Slides:  http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhomeAbout ARRY-502 and CRTh2A
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
2. Enterprise Europe Network - Sport Meets Business: How Entrepreneurs Beat the Recession
3. Rockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose
4. Omnetics Meets Increasing Demands of Miniature Electronics Industry with Custom Designed Micro and Nano Cables
5. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
6. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
7. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
8. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
9. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
10. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
11. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014   Fruit Street ... secured an initial seed round of funding. ... was led by a series of individual investors, the ... whom participated in the initial round are; Houston ... Medical Center Urologist Stacy Childs, Rapha Family Medicine Practice ...
(Date:9/18/2014)... Pharma IQ, after huge demand ... Countdown calendar to cover the years 2014 - 2018 ... shows the serialisation requirements around the globe and the ... For companies dealing with international markets, serialisation ... they will have to comply with new regulations coming ...
(Date:9/18/2014)... , Sept. 18, 2014   3D Systems   (NYSE: ... Simbionix RobotiX Mentor™ , a new robotic surgery skills ... first time at the ERUS exhibition in Amsterdam, ... #7). Robotic-assisted minimally invasive surgery represents a growing ... the needs for training for robotic surgery has increased, and ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 23D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3
... Biomerix Corporation announced today that it has received ... mesh allowing for the marketing of REVIVE in all ... clearance from the U.S. Food and Drug Administration (FDA) ... the Biomerix Biomaterial™, a proprietary, biointegrative synthetic tissue scaffold. ...
... ANNAPOLIS, Md., Jan. 24, 2011 PharmAthene, Inc. (NYSE Amex: ... the Delaware Court of Chancery, which commenced January 3, 2011, ... this past Friday, January 21, 2011. The Company anticipates that ... in front of the court will be complete by the ...
Cached Medicine Technology:Biomerix Granted CE Mark for its REVIVE™ Soft Tissue Repair Mesh 2PharmAthene Provides Update on Litigation With SIGA Technologies 2
(Date:9/18/2014)... is good for you. But new research from University ... added benefit for cancer patients undergoing chemotherapy. , Their ... that combining exercise with chemotherapy shrunk tumors more than ... in the School of Nursing and director of the ... senior author on the study, which appears in the ...
(Date:9/18/2014)... September 18, 2014 TayganPoint Consulting ... today that President and co-founder John Cassimatis was ... Award Winners for 2014, recognizing the region’s top ... an emerging executive of the year. , The ... life sciences that continue to shape the medical ...
(Date:9/18/2014)... September 18, 2014 Ben Quirk, CEO ... Ormond, Jr. Leadership Award by the Savannah Science Seminar ... and wellness throughout the nation and especially in Savannah. ... award,” said Ben. “The Savannah Science Seminar is an ... and multiple generations have gone through the program,” he ...
(Date:9/18/2014)... new method to study Ebola virus in wildlife. Video ... (WCS)-led research, published today in the journal PLOS ... samples from wild great apes to identify populations likely ... a new tool for performing large, population-scale field assessments ... studied and improve our understanding of the virus, distribution ...
(Date:9/18/2014)... The National Institutes of Health (NIH) recently awarded the ... grant to the Los Angeles Biomedical Research Institute (LA ... a vaccine to protect patients from the healthcare-related infections, ... (MRSA). , The National Institute of Allergy and ... to LA BioMed infectious disease specialists John E. Edwards, ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... ITASCA, Ill., March 20 Arthur J. ... Healthcare Risk Solutions, LLC,headquartered in Fort Washington, ... Founded in 2002, Healthcare Risk Solutions, ... professional liability insurance,products, associated risk mitigation consulting ...
... PRGO ; TASE) today announced that the ... Jersey has denied Connetics Corporation,s motion,for a preliminary ... generic equivalent to Connetics, Olux(R) Foam and has,lifted ... launching,the product. The Court also denied Perrigo,s motion ...
... emotional well-being, study suggests , , THURSDAY, March 20 (HealthDay ... health of the husband -- as either patient or ... of mind, new research suggests. , The finding suggests ... his wife,s experience of psychological distress more so than ...
... WASHINGTON, March 20 Veterans in seven,additional states ... Department of Veterans Affairs (VA) plan to open 14 ... James B. Peake today,announced that VA will establish new ... "VA is dedicated to providing the best in ...
... was a rainy,Saturday, nothing could dampen the spirits ... Free Families (DCTFF) hosted a special evening at,Saturday,s ... over 100 D.C.,residents who have quit smoking using ... Health Care, Inc., (Photo: http://www.newscom.com/cgi-bin/prnh/20080320/NETH063 ...
... halve by 2015 the number of people without toilet access ... every dollar spent installing toilets in developing countries, there would ... according to a UN report released today. , The UN ... 2015 the number of people worldwide who don,t have access ...
Cached Medicine News:Health News:Perrigo Company Announces Launch of Clobetasol Propionate Foam 2Health News:Perrigo Company Announces Launch of Clobetasol Propionate Foam 3Health News:Cancer Poses Challenges for Husbands' Frame of Mind 2Health News:Cancer Poses Challenges for Husbands' Frame of Mind 3Health News:VA to Open 14 New Clinics in Seven States 2Health News:Quitters Honored at Wizards' DC Tobacco Free Family Night 2Health News:Cleaning Up the World's Sanitation 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: